Overview
Adlai Nortye Ltd. is a biopharmaceutical company based in China, specifically involved in the research and development of innovative immunotherapies for cancer. The company operates primarily in the oncology sector, focusing its efforts on developing therapies that engage the body's own immune system to fight cancer. Key projects include a range of clinical-stage programs targeting various stages and types of cancer, with notable drugs in their pipeline being immune checkpoint inhibitors and bi-specific antibodies. Adlai Nortye is committed to advancing these programs through clinical trials with the aim of improving survival and quality of life for cancer patients worldwide. The company's strategic initiatives reflect a blend of scientific innovation and collaboration with global biotechnology entities to expedite the development and commercialization of its therapeutic products.
AI+ Ask Fintel’s AI assistant about Adlai Nortye Ltd. - Depositary Receipt (Common Stock).
Thinking about good questions…
Basic Stats
The share price of Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of September 5, 2025 is $1.75 / share. This is an increase of 4.79% from the prior week.
The Factor Analysis chart (below right) shows a view of Adlai Nortye Ltd. - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 0.00 MM |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 5.43 |
| Short Shares Avail. | 0.01 MM |
| Short Interest | 0.01 MM |
| Short Float | |
| Days to Cover | 0.86 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -25.85 % |
| Volatility (1 yr) | 1.36 |
| Beta | 0.78 |
| Sharpe Ratio (1 yr) | -0.22 |
| Sortino Ratio (1 yr) | -0.27 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.48 |
| ROE | -0.97 |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) is $9.18. The forecasts range from a low of $9.09 to a high of $9.45. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Adlai Nortye Ltd. - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-10-24 | Cantor Fitzgerald | Overweight | Initiate | |
| 2024-06-20 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-09-04 | HC Wainwright & Co. | Buy | Initiate | |
| 2024-10-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-02 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
